PCV81 Cost-Effectiveness of Apixaban For Stroke Prevention In Atrial Fibrillation: An Kazakhstan Perspective

Kostyuk, A; Almadiyeva, A; Nurgozhin, T

NUR Home
→
02.National Laboratory Astana
→
Articles
→
View Item

Advanced Search

Система будет остановлена для регулярного обслуживания. Пожалуйста, сохраните рабочие данные и выйдите из системы.

PCV81 Cost-Effectiveness of Apixaban For Stroke Prevention In Atrial Fibrillation: An Kazakhstan Perspective

Kostyuk, A; Almadiyeva, A; Nurgozhin, T

URI: https://www.sciencedirect.com/science/article/pii/S1098301517315619
http://nur.nu.edu.kz/handle/123456789/2963

Date: 2017-10-01

Abstract:

Apixaban, dabigatran, and rivaroxaban are 3 novel oral anticoagulants (NOACs) currently approved for stroke prevention in patients with atrial fibrillation (AF). Although warfarin remains the standard of care in Kazakhstan.The objective of this study was to evaluate the cost-effectiveness of apixaban against other NOACs and warfarin from the considering costs and savings for public payers perspective in Kazakhstan

Show full item record